This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2024 Mar 12;10(1):89-91.

doi: 10.3233/BLC-249001. eCollection 2024.

BCG in Immunocompromised Patients: Is it effective? Is it safe?

Edward M Messing¹

Affiliations

PMID: 38993531
PMCID: PMC11181704
DOI: 10.3233/BLC-249001

BCG in Immunocompromised Patients: Is it effective? Is it safe?

Edward M Messing. Bladder Cancer. 2024.

. 2024 Mar 12;10(1):89-91.

doi: 10.3233/BLC-249001. eCollection 2024.

Author

Edward M Messing¹

Affiliation

¹ University of Rochester Medical Center, Rochester, NY, USA.

PMID: 38993531
PMCID: PMC11181704
DOI: 10.3233/BLC-249001

No abstract available

PubMed Disclaimer

Conflict of interest statement

The author has no conflicts of interest to report.

Similar articles

Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
Herr HW, Dalbagni G. Herr HW, et al. BJU Int. 2013 May;111(6):984-7. doi: 10.1111/j.1464-410X.2012.11778.x. Epub 2013 Jan 25. BJU Int. 2013. PMID: 23351086
Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population.
Kim EY, Lim JE, Jung JY, Son JY, Lee KJ, Yoon YW, Park BH, Moon JW, Park MS, Kim YS, Kim SK, Chang J, Kang YA. Kim EY, et al. BMC Infect Dis. 2009 Dec 15;9:207. doi: 10.1186/1471-2334-9-207. BMC Infect Dis. 2009. PMID: 20003535 Free PMC article.
Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis.
Derrick SC, Dao D, Yang A, Kolibab K, Jacobs WR, Morris SL. Derrick SC, et al. PLoS One. 2012;7(3):e32959. doi: 10.1371/journal.pone.0032959. Epub 2012 Mar 19. PLoS One. 2012. PMID: 22442674 Free PMC article.
Bacille Calmette-Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010-2017.
Nunes-Santos CJ, Rosenzweig SD. Nunes-Santos CJ, et al. Front Immunol. 2018 Jun 22;9:1423. doi: 10.3389/fimmu.2018.01423. eCollection 2018. Front Immunol. 2018. PMID: 29988375 Free PMC article. Review.
Cutaneous complications of BCG vaccination in infants with immune disorders: two cases and a review of the literature.
Antaya RJ, Gardner ES, Bettencourt MS, Daines M, Denise Y, Uthaisangsook S, Buckley RH, Prose NS. Antaya RJ, et al. Pediatr Dermatol. 2001 May-Jun;18(3):205-9. doi: 10.1046/j.1525-1470.2001.018003205.x. Pediatr Dermatol. 2001. PMID: 11437999 Review.

See all similar articles

References

1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al.. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59:389–402. - PubMed
1. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol. 2016;196:1021–1029. - PubMed
1. Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: An update. J Can Urol Assoc. 2009;3:S199, 10.5489/cuaj.1196. - DOI - PMC - PubMed
1. Frau JG, Palou J, Rodríguez O, Parada R, Breda A, Villavicencio H. Failure of bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: definition and treatment options. Arch Esp Urol. 2016;69:423–433. - PubMed
1. Witjes JA. Management of BCG failures in superficial bladder cancer: A review. Eur Urol. 2006;49:790–797,10.1016/J.EURURO.2006.01.017. - DOI - PubMed

LinkOut - more resources

Full Text Sources
- Atypon
- PubMed Central